找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Chronic Myeloid Leukemia; Rüdiger Hehlmann Book 20161st edition Springer International Publishing Switzerland 2016 Chronic myeloid leukaem

[复制链接]
楼主: Garfield
发表于 2025-3-25 07:04:04 | 显示全部楼层
发表于 2025-3-25 10:43:44 | 显示全部楼层
发表于 2025-3-25 12:16:27 | 显示全部楼层
发表于 2025-3-25 16:43:04 | 显示全部楼层
https://doi.org/10.1007/978-3-030-34898-4n has focused on the need to define and validate levels of deeper molecular response (MR) within the context of the IS. While there has been substantial progress, . measurement is technically challenging and standardization is an ongoing process.
发表于 2025-3-25 22:12:24 | 显示全部楼层
Franz Breuer,Petra Muckel,Barbara Dierisbe recommended for patients with a well matched donor and low risk transplant profile as early as possible. It is discouraged for patients with failed response to multiple TKIs and no matched donor. Close interaction between CML physicians and transplant centers facilitates such a targeted risk adapted approach.
发表于 2025-3-26 01:20:34 | 显示全部楼层
,Gütekriterien und ethische Fragen,ost importance even for drug companies. It should be considered the future criterion to evaluate the success of clinical trials, especially if we want to take into account quality of life of patients and also the economic aspect..The question of cure in CML is now one of the major concerns and has to be considered in the management of the disease.
发表于 2025-3-26 04:29:39 | 显示全部楼层
Standardization of Molecular Monitoring for Chronic Myeloid Leukemia,n has focused on the need to define and validate levels of deeper molecular response (MR) within the context of the IS. While there has been substantial progress, . measurement is technically challenging and standardization is an ongoing process.
发表于 2025-3-26 09:34:53 | 显示全部楼层
发表于 2025-3-26 15:38:21 | 显示全部楼层
发表于 2025-3-26 18:54:50 | 显示全部楼层
Response-Related Predictors of Survival in CML,h of treatment can be considered if unfavorable outcome has to be expected due to early response failure. Numerous studies have demonstrated the association of long-term outcome with early response for first-line treatment with imatinib, with second-generation TKI, and for second-line TKI treatment as well.
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-6-27 02:45
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表